JMP Securities Initiates Astria Therapeutics (ATXS) at Market Outperform

JMP Securities analyst Jonathan Wolleben initiated Astria Therapeutics (NASDAQ: ATXS) at Market Outperform with a price target of $26.00.

The analyst commented, “Astria is using its half-life extension technology to develop long-acting mAbs targeting derisked targets in large, proven markets. Its lead candidate, navenibart, is starting Phase 3 testing to prevent hereditary angioedema (HAE) attacks, while its second candidate, STAR-0310, is starting clinical testing for atopic dermatitis.”

For an analyst ratings summary and ratings history on Astria Therapeutics click here. For more ratings news on Astria Therapeutics click here.

Shares of Astria Therapeutics closed at $7.49 yesterday.

You May Also Be Interested In

• Freedom Broker Upgrades Serve Robotics (SERV) to Buy
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
• Jane Street Took $15 Billion Hit In July Tied To Situational Awareness - Reuters